Form 4: Herbalife Grants Michael Johnson Equity Awards

Herbalife Ltd. granted Executive Chairman Michael Johnson 72,689 restricted stock units and 399,619 stock appreciation rights, vesting over two years.

Summary

• Michael Johnson, Executive Chairman and Director of Herbalife Ltd., was granted equity awards on February 25, 2026.
• He received 72,689 restricted stock units (RSUs) under the company's Amended and Restated 2023 Stock Incentive Plan.
• These RSUs will vest in two equal installments: 50% on February 25, 2027, and the remaining 50% on February 25, 2028, contingent on his continued service.
• Additionally, Johnson was granted 399,619 stock appreciation rights (SARs) with an exercise price of $10.51.
• The SARs also vest in two equal installments: 50% on February 25, 2027, and 50% on February 25, 2028, subject to his continued service.
• Following these transactions, Johnson beneficially owns 887,415 shares of common stock and 399,619 SARs.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices aimed at retaining key leadership and aligning interests with shareholders, without indicating any immediate operational or financial shifts.

Positives

• The equity grants align the Executive Chairman's interests with those of shareholders, incentivizing long-term performance.
• The multi-year vesting schedule for both RSUs and SARs promotes executive retention and stability in leadership.
• The use of a pre-existing stock incentive plan (Amended and Restated 2023 Stock Incentive Plan) indicates a structured approach to executive compensation.

Negatives

• The issuance of new equity awards could lead to potential future dilution for existing shareholders upon vesting and exercise.
• These grants represent a future compensation expense for the company, impacting profitability metrics.

Risks

• Executive Retention Risk: The vesting of RSUs and SARs is contingent on continued service, meaning if Michael Johnson departs before vesting dates, the unvested awards would be forfeited.
• Stock Price Volatility Risk: The value realized from SARs is directly tied to the future stock price performance of Herbalife, exposing the compensation to market fluctuations.
• Dilution Risk: While not immediate, the future vesting and conversion of RSUs and exercise of SARs will increase the number of outstanding shares, potentially diluting existing shareholder value.

Future Outlook

The grants of RSUs and SARs are designed to incentivize Michael Johnson's continued service through February 25, 2028, aligning his future compensation with the company's long-term performance. The SARs have an expiration date of February 25, 2036, indicating a long-term incentive horizon.

Industry Context

StockSavvy.ai notes that equity-based compensation, such as RSUs and SARs, is a standard practice across industries, particularly for executive-level employees. This approach is widely used to attract, retain, and motivate key personnel by linking their financial incentives directly to the company's stock performance and long-term success. The structure of these grants, with multi-year vesting, is consistent with typical executive retention strategies in the consumer goods and direct selling sectors.

Comparison to Industry Standards

• The grant of RSUs and SARs to an Executive Chairman is a common practice in publicly traded companies, comparable to compensation structures seen at companies like Nu Skin Enterprises (NUS) or USANA Health Sciences (USNA), which also operate in the direct selling industry.
• The vesting schedule of 50% in one year and 50% in the subsequent year is a relatively standard two-year cliff or graded vesting schedule, often used to ensure executive commitment over a medium-term horizon.
• The SARs, with an exercise price of $10.51, provide upside potential tied to stock price appreciation, similar to stock options or performance share units used by peers.

Corporate Governance

Related Party Transactions

• The transaction involves an equity grant to Michael Johnson, an executive officer and director, which is a related party transaction, but it is a standard compensation practice disclosed as required.

Stakeholder Impact

• Shareholders: Potential future dilution upon vesting and exercise of awards; increased alignment of executive interests with shareholder value.
• Employees: No direct impact on general employees, but it signals the company's commitment to executive retention.
• Management: Michael Johnson's compensation is enhanced, incentivizing his continued leadership and performance.

Next Steps

• Michael Johnson's continued service through February 25, 2027, for the first tranche of vesting.
• Michael Johnson's continued service through February 25, 2028, for the second tranche of vesting.
• Potential exercise of SARs by February 25, 2036, if the stock price appreciates above the exercise price.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation and does not provide new information that would fundamentally alter the investment thesis for Herbalife. It reflects standard corporate governance practices for executive retention and incentive alignment. Therefore, a "hold" recommendation is appropriate, as this filing alone does not present a compelling reason to buy or sell the stock, but rather confirms ongoing operational aspects.

Keywords

Herbalife, HLF, Michael Johnson, Executive Compensation, Restricted Stock Units, RSUs, Stock Appreciation Rights, SARs, Equity Grant, Form 4, Insider Transaction, Corporate Governance, Executive Retention